Brandon Capital

🚀 Exciting progress from Brandon Capital portfolio company ENA Respiratory, whose new formulation improves stability and has a shelf life of over two years at room temperature. 🌟 Successfully completed the single ascending dose phase of their Phase Ib study for the dry powder formulation of INNA-051. 🌟 Now moving into the multiple ascending dose phase. 🌟 Significant step forward in protecting at-risk populations from respiratory viral infections. With results expected later this year, we're eagerly watching as ENA progresses toward their mission of driving impactful innovations in respiratory health globally. #Biotech #Innovation #RespiratoryHealth #PortfolioSuccess Photo by Vlada Karpovich

🎙️ Podcast: Phase III is an excellent new science podcast, and we’re delighted that Brandon Portfolio company Certa Therapeutics CEO Professor Darren Kelly was invited to join their inaugural series on chronic kidney disease. 🎧 Listen to Darren with his futurist hat on, chatting with Rachel Williamson in a free-ranging conversation that covered what's next and why therapies targeting GPR68 will play an important role in reducing fibrosis and inflammation in end organs such as the kidneys. 🔵Certa identified GRP68 as a master regulator of fibrosis. 🔵Molecular signature mapping identifies pathways changed by inflammation and fibrosis. 🔵How FT-011 blocks or modulates these pathways in the right direction to reduce inflammation and fibrosis. Certa’s pioneering research and results to date are exceptional, and we’re very excited about their upcoming Phase II clinical trials for Scleroderma and Chronic Kidney Disease. PS It’s wonderful to have a local science podcast covering what’s happening in the local sector, so please support by subscribing! #Biotech #ChronicKidneyDisease #Innovation #Fibrosis #KidneyHealth #LifeSciences #BrandonCapital https://lnkd.in/eR2DkamB

We were thrilled to have Leighton Read in the spotlight at Tuesday's event: What's next for biotech? Current insights from four decades in Silicon Valley biotech investing - with Leighton Read MD. Along with our event partners RSM Australia and Brandon Capital, we welcomed stakeholders from across WA's MTP sector as well as interstate guests from the Brandon Capital Investment Review Committee. As a medical trained doctor and investor with decades of experience, Leighton shared valuable insights about Venture Capital: ⭐When you have your first meeting with a VC, your aim is not to immediately be invested in - the aim is to get another meeting ⭐Be likeable, and make it easy to find out if you're a good investment ⭐The weighting between investing in the tech or investing in the people goes towards people - you can pivot the tech or your market if you have a smart team ⭐Network, network, network! We also talked about AI and its impact on innovation development and VC: ⭐The impact of AI will be felt across all stages of developing medical innovations, and most so in the early stages of the commercialisation process ⭐It's going to be most disruptive for those who don't want to think about it - dip your toes in! ⭐AI will become a part of the way that investors make their decisions Want to keep the great conversations going about AI? Save the date for our next WA MTP Sector Spotlight ‘AI in Health: what can we do now’ on Thursday September 19 at the Harry Perkins Institute of Medical Research (North) 5-7:30pm. MTPConnect | The University of Western Australia | Department of Jobs, Tourism, Science and Innovation | Department of Health (WA Health) | Tracey Wilkinson | Kevin Pfleger

👏🏿👏🏽👏to Brandon Capital Portfolio Company George Medicines who've announced that they've filled a New Drug Application to the FDA for GMRx2, their pioneering triple-combination pill aimed at revolutionising the treatment of hypertension. It's a significant milestone towards addressing one of the world's most prevalent chronic conditions. 💡GMRx2 is designed to provide an effective, all-in-one solution for managing hypertension, potentially reducing the need for multiple medications. 🌐 Hypertension affects over 1 billion people worldwide and if approved, GMRx2 represents a major advancement in making treatment more accessible and effective for patients everywhere. 🔬Backed by rigorous research and clinical trials, George Medicines is committed to ensuring the highest standards of safety and efficacy. Congratulations to Mark Mallon and the George Medicines team and to Brandon Capital Managing Partner Stephen Thompson Senior Investment Manager Ingmar Wahlqvist and Analyst Melissa Byrne 🔗 Here's the full announcement https://lnkd.in/gs2jr_XS #HealthcareInnovation #Hypertension #GeorgeMedicines #BrandonCapital

👏🏽👏🏽👏🏽To all the panellists at the annual #bioconnections conference today and was great to see our Senior Investment Manager, Ingmar Wahlqvist, contributing to the Investor panel. Thanks to Sarah Meibusch for an excellent summary of the panel themes 👇🏽

📣Congratulations to Brandon Portfolio Company Certa Therapeutics which today announced that the European Medicines Agency has granted Orphan Drug Designation (ODD) for its lead drug candidate, FT011, as a potential treatment of Systemic Sclerosis (SSc). Certa is developing innovative precision therapies for patients with inflammatory and fibrotic diseases and has previously received ODD and Fast Track designation for FT011 as a potential treatment of SSc from the U.S. FDA. #biotech #orphandrugs #innovation #certa Article 👇🏽 https://lnkd.in/g4aKwqin

⏰🚀 Deadline alert! Applications for the Victorian Biotech Innovators program close tomorrow. Don't miss this opportunity to: 💡Learn from and connect with internationally experienced biotech leaders 💡Access exclusive coaching and industry insights 💡Build a business plan for a research idea 💡Join a network of like-minded local innovators and pioneers Huge thanks to everyone who's shared and commented to help amplify the program's reach! Apply 👇🏿 https://lnkd.in/gvRNiceP Learn more 👇🏿 https://lnkd.in/gBK_h6WN Delivered thanks to support from the Department of Jobs, Skills, Industry and Regions

➡️ 📅 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝗘𝘅𝘁𝗲𝗻𝘀𝗶𝗼𝗻: 𝗡𝗼𝘄 𝗧𝘂𝗲𝘀𝗱𝗮𝘆 𝟮𝟯 𝗝𝘂𝗹𝘆 𝗮𝘁 𝟱𝗽𝗺! The Brandon Capital team will present alongside an impressive international guest speaker lineup in our upcoming Biotech Innovators Program. Applying drug development theory in hands-on workshops, you'll build a business case for an innovation in four monthly seminars with support from biotech industry experts. Designed for Victorian-based researchers, entrepreneurs, and tech transfer experts, the program is perfect for anyone wanting to learn the process of turning an innovative idea into a potential therapy. Apply 👇🏽 https://lnkd.in/gUNPw7Tj Learn more 👇🏽 https://lnkd.in/gBK_h6WN Delivered thanks to support from the Department of Jobs, Skills, Industry and Regions #Biotech #Innovation #Entrepreneurship #TechTransfer

🚀🚀🚀 Congratulations to Brandon Capital Portfolio Company CatalYm GmbH on your $150 million Series D announcement. As an early investor, it's been a privilege to follow your team's achievements, and we're optimistic about your plans to: 🌟Advance your lead program for #visugromab in randomised Phase 2b trials. 🌟Expand #visugromab's late-stage clinical development into earlier lines of treatment. The round was led by Canaan and Bioqube Ventures, with new investors Forbion Growth, Omega Funds and Gilde Healthcare joining other insiders JEITO, Forbion, BGV (BioGeneration Ventures), Novartis Ventures Funds and Vesalius. We're also incredibly proud of our UK-based Partner, Jonathan Tobin, for his championing this incredible company. "Visugromab has demonstrated ground-breaking efficacy and safety in its Phase 2a GDFATHER study, and we are excited by the potential of this drug to generate deep and durable remissions in advanced cancer patients. This is why we do what we do!"

🚀🚀🚀 Congratulations to Brandon Capital Portfolio Company CatalYm GmbH on your $150 million Series D announcement. As an early investor, it's been a privilege to follow your team's achievements, and we're optimistic about your plans to: 🌟Advance your lead program for #visugromab in randomised Phase 2b trials. 🌟Expand #visugromab's late-stage clinical development into earlier lines of treatment. The round was led by Canaan and Bioqube Ventures, with new investors Forbion Growth, Omega Funds and Gilde Healthcare joining other insiders JEITO, Forbion, BGV (BioGeneration Ventures), Novartis Ventures Funds and Vesalius. We're also incredibly proud of our UK-based Partner, Jonathan Tobin, for his championing this incredible company. "Visugromab has demonstrated ground-breaking efficacy and safety in its Phase 2a GDFATHER study, and we are excited by the potential of this drug to generate deep and durable remissions in advanced cancer patients. This is why we do what we do!"